Adherex Announces Publication of ADH-1 Study in Cancer Research
2008年5月15日 - 9:30PM
Marketwired
RESEARCH TRIANGLE PARK, NORTH CAROLINA (AMEX: ADH), a
biopharmaceutical company devoted to solving problems for patients
with cancer, announced today that the results of a preclinical
study of ADH-1 in combination with chemotherapy were published in
the May issue of Cancer Research. The study, entitled "Targeting
N-Cadherin Enhances Antitumor Activity of Cytotoxic Therapies in
Melanoma Treatment,"(1) was conducted by Dr. Douglas Tyler and
colleagues at the Duke Comprehensive Cancer Center.
In the study, the researchers noted a 30-fold reduction in tumor
size following treatment with ADH-1 and melphalan chemotherapy
compared to the chemotherapy alone. The combination of ADH-1 and
melphalan produced frequent, durable and complete tumor regression
in the human xenograft melanoma models. In addition to the
significant synergy, ADH-1 in combination with melphalan was also
shown to produce responses in tumors resistant to melphalan, where
neither agent alone produced tumor regression.
"We tested ADH-1, a compound that can weaken the tumor by
targeting the N-cadherin expressed on the surface of a melanoma
cell, in combination with chemotherapy. When chemotherapy was
applied to the tumor in this weakened state, it was much more
effective compared to conventional therapy alone," said Douglas
Tyler, M.D., a surgeon at Duke and the Durham Veterans Affairs
Medical Center, and senior investigator on this study. "These
results are extremely significant because they may help us better
treat patients with this deadly condition."
Tyler continued, "We saw a complete regression of the tumors in
the animal model when we used the regional melphalan chemotherapy
in combination with ADH-1, which is far better than anything we
have seen before with the chemotherapy alone. Furthermore, the
addition of ADH-1 produced no additional side effects, which is an
important consideration in cancer treatment."
The synergy observed in the study has led Adherex to rapidly
move into clinical studies where we are evaluating ADH-1 in
combination with melphalan via isolated limb infusion for the
treatment of melanoma in an ongoing multi-institutional Phase I/IIB
trial. Current participating centers include Duke University
Medical Center, MD Anderson Cancer Center, Lehigh Valley Hospital
and H. Lee Moffitt Cancer Center, with plans to add up to four
additional centers. The trial is expected to enroll a total of 56
patients, and has already accrued 33 patients to date.
The results of the Phase I and initial Phase IIB data from this
study will be presented at the 2008 American Society of Clinical
Oncology (ASCO) Annual Meeting, which takes place May 30 - June 3,
2008 in Chicago, IL. The poster discussion presentation entitled "A
phase I/II study of systemic ADH-1 in combination with isolated
limb infusion with melphalan (ILI-M) in patients with locally
advanced in-transit melanoma" is scheduled to be presented on June
1, 2008.
Earlier this year, Adherex was granted orphan drug designation
for the use of ADH-1 in conjunction with melphalan for the
treatment of Stage IIB/C, III, and IV malignant melanoma.
(1) Augustine CK, Yoshimoto Y, Gupta M, Zipfel PA, Selim MA,
Febbo P, Pendergast AM, Peters WP, Tyler DS: Targeting N-Cadherin
Enhances Antitumor Activity of Cytotoxic Therapies in Melanoma
Treatment. Cancer Res 2008; 68(10); 1-8.
About Adherex Technologies
Adherex Technologies Inc. is a biopharmaceutical company
dedicated to the discovery and development of novel cancer
therapeutics. We are in the business of solving problems for
patients with cancer. We have multiple products in the clinical
stage of development, including eniluracil, ADH-1 and sodium
thiosulfate (STS). Eniluracil, an oral dihydropyrimidine
dehydrogenase (DPD) inhibitor, is being developed to improve the
tolerability and effectiveness of 5-fluorouracil (5-FU), one of the
most widely used oncology drugs in the world. ADH-1 is a
biotechnology compound which selectively targets N-cadherin, a
protein present on certain tumor cells and the blood vessels of
solid tumors. STS is a chemoprotectant being developed to reduce or
prevent hearing loss that may result from treatment with
platinum-based chemotherapy drugs. With a diversified portfolio of
unique preclinical and clinical-stage cancer compounds and a
management team with expertise in identifying, developing and
commercializing novel cancer therapeutics, Adherex aims to become a
leader in developing innovative treatments that address important
unmet medical needs in cancer. For more information, please visit
our website at www.adherex.com.
This press release contains forward-looking statements that
involve significant risks and uncertainties. The actual results,
performance or achievements of the Company might differ materially
from the results, performance or achievements of the Company
expressed or implied by such forward-looking statements. Such
forward-looking statements include, without limitation, those
regarding the development plans of the Company and the expected
timing or results of our development. We can provide no assurance
that such development will proceed as currently anticipated or that
the expected timing or results of such development will be
realized. We are subject to various risks, including the
uncertainties of clinical trials, drug development and regulatory
review, the early stage of our product candidates, our reliance on
collaborative partners, our need for additional capital to fund our
operations, our history of losses, and other risks inherent to the
biopharmaceutical industry. For a more detailed discussion of
related risk factors, please refer to our public filings available
at www.sedar.com and www.sec.gov.
Contacts: Adherex Technologies Inc. D. Scott Murray Senior Vice
President, Corporate Development 919-484-8484 info@adherex.com
Adherex (AMEX:ADH)
過去 株価チャート
から 4 2024 まで 5 2024
Adherex (AMEX:ADH)
過去 株価チャート
から 5 2023 まで 5 2024